AdvaMed® 2024 State Policy Briefing: State Data Privacy Legislation

As patient advocates, we’ve witnessed countless stories of hope deferred and lives put on hold while Medicare beneficiaries wait several years for access to breakthrough medical technologies that the FDA has already deemed safe and effective. This unacceptable delay between innovation and access must end. Innovation does not benefit patients without coverage.

WASHINGTON—AdvaMed, the world’s largest trade association representing medtech innovators, today welcomed a letter from U.S. Senators Susan Collins (R-Maine) and Jeanne Shaheen (D-N.H.), co-chairs of the Senate Diabetes Caucus, and U.S. Representatives Diana DeGette (D-Colo.-01) and Gus Bilirakis (R-Fla.-12), co-chairs of the U.S. House Diabetes Caucus, to Centers for Medicare and Medicaid Services (CMS) Administrator Mehmet Oz urging the agency not to finalize a proposal the lawmakers warned could reduce and complicate patient access to continuous glucose monitors (CGMs) and durable insulin pumps.

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:

WASHINGTON—AdvaMed, the medtech association, today thanked the U.S. House Energy and Commerce Health Subcommittee for highlighting the need for Medicare coverage of FDA-authorized breakthrough medtech and releasing a discussion draft of breakthrough coverage legislation at a hearing, “Examining Policies to Enhance Seniors’ Access to Breakthrough Medical Technologies.” 

WASHINGTON—AdvaMed, the medtech association, today welcomed U.S. House of Representatives Committee on Ways and Means passage of legislation providing Medicare coverage of FDA-designated and authorized breakthrough medtech. AdvaMed also urged legislators to add diagnostic tests to the measure, the Ensuring Patient Access to Critical Breakthrough Products Act, H.R. 5343.